The remarkable antitumor efficacy of corticosteroid treatment in patients with refractory thymomas

IF 2.4 Q2 RESPIRATORY SYSTEM
Tomohiro Tanaka , Yasushi Goto , Ken Masuda , Yuki Shinno , Yuji Matsumoto , Yusuke Okuma , Tatsuya Yoshida , Hidehito Horinouchi , Noboru Yamamoto , Yuichiro Ohe
{"title":"The remarkable antitumor efficacy of corticosteroid treatment in patients with refractory thymomas","authors":"Tomohiro Tanaka ,&nbsp;Yasushi Goto ,&nbsp;Ken Masuda ,&nbsp;Yuki Shinno ,&nbsp;Yuji Matsumoto ,&nbsp;Yusuke Okuma ,&nbsp;Tatsuya Yoshida ,&nbsp;Hidehito Horinouchi ,&nbsp;Noboru Yamamoto ,&nbsp;Yuichiro Ohe","doi":"10.1016/j.resinv.2024.06.008","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Some case reports have found that corticosteroid treatments shrunk thymoma lesions remarkably after the failure of chemotherapy or surgery. However, few studies have comprehensibly evaluated the antitumor effects of corticosteroids in patients with invasive thymomas.</p></div><div><h3>Methods</h3><p>We reviewed the medical records of 13 consecutively enrolled patients with locally advanced or metastatic thymomas treated via corticosteroid monotherapies from January 2010 to March 2021 in our institute. A Cox's proportional hazard model and the Kaplan-Meier method were used to identify factors associated with survival.</p></div><div><h3>Results</h3><p>The median follow-up time was 26 months (range, 13–115 months). The median initial dose of corticosteroid was 0.90 mg/kg/day prednisolone equivalent (range, 0.4–1.1 mg/kg/day). Of the 13 cases, 7 (53.8%, 95% CI: 0.25–0.81) exhibited a partial response and 5 (38.5%, 95% CI: 0.14–0.68) stable disease. The median progression-free survival was 5.7 months [95% confidence interval (CI): 1.5–9.6 months]. The median overall survival was 25.3 months (95% CI: 7.1–not attained). The median duration of corticosteroid use was 3 months (range, 1–64 months). Patients with WHO subtype B thymomas exhibited a better overall response rate to corticosteroids than did patients with other disease subtypes (75%, 95% CI: 0.19–0.99). Adverse events of Grade 3 or more were not observed.</p></div><div><h3>Conclusions</h3><p>Corticosteroids are clinically valuable for patients with thymomas.</p></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory investigation","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S221253452400100X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Some case reports have found that corticosteroid treatments shrunk thymoma lesions remarkably after the failure of chemotherapy or surgery. However, few studies have comprehensibly evaluated the antitumor effects of corticosteroids in patients with invasive thymomas.

Methods

We reviewed the medical records of 13 consecutively enrolled patients with locally advanced or metastatic thymomas treated via corticosteroid monotherapies from January 2010 to March 2021 in our institute. A Cox's proportional hazard model and the Kaplan-Meier method were used to identify factors associated with survival.

Results

The median follow-up time was 26 months (range, 13–115 months). The median initial dose of corticosteroid was 0.90 mg/kg/day prednisolone equivalent (range, 0.4–1.1 mg/kg/day). Of the 13 cases, 7 (53.8%, 95% CI: 0.25–0.81) exhibited a partial response and 5 (38.5%, 95% CI: 0.14–0.68) stable disease. The median progression-free survival was 5.7 months [95% confidence interval (CI): 1.5–9.6 months]. The median overall survival was 25.3 months (95% CI: 7.1–not attained). The median duration of corticosteroid use was 3 months (range, 1–64 months). Patients with WHO subtype B thymomas exhibited a better overall response rate to corticosteroids than did patients with other disease subtypes (75%, 95% CI: 0.19–0.99). Adverse events of Grade 3 or more were not observed.

Conclusions

Corticosteroids are clinically valuable for patients with thymomas.

皮质类固醇治疗对难治性胸腺瘤患者的抗肿瘤疗效显著。
背景:一些病例报告发现,在化疗或手术失败后,皮质类固醇治疗可显著缩小胸腺瘤病灶。然而,很少有研究全面评估了皮质类固醇对侵袭性胸腺瘤患者的抗肿瘤作用:我们回顾了我院自 2010 年 1 月至 2021 年 3 月连续收治的 13 例局部晚期或转移性胸腺瘤患者的病历。采用Cox比例危险模型和Kaplan-Meier方法确定与生存相关的因素:中位随访时间为26个月(13-115个月)。皮质类固醇初始剂量的中位数为 0.90 毫克/千克/天的泼尼松龙当量(范围为 0.4-1.1 毫克/千克/天)。在13例患者中,7例(53.8%,95% CI:0.25-0.81)出现部分应答,5例(38.5%,95% CI:0.14-0.68)病情稳定。中位无进展生存期为 5.7 个月[95% 置信区间(CI):1.5-9.6 个月]。中位总生存期为 25.3 个月(95% 置信区间:7.1-未达到)。使用皮质类固醇的中位时间为3个月(1-64个月)。与其他疾病亚型患者相比,WHO B亚型胸腺瘤患者对皮质类固醇的总体反应率更高(75%,95% CI:0.19-0.99)。未观察到3级或以上的不良反应:皮质类固醇对胸腺瘤患者具有临床价值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Respiratory investigation
Respiratory investigation RESPIRATORY SYSTEM-
CiteScore
4.90
自引率
6.50%
发文量
114
审稿时长
64 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信